Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Loargys 5 mg/ml solution for injection/infusion

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Pegzilarginase may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Pegzilarginase
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Loargys contains the active substance pegzilarginase, which is a modified human enzyme produced by recombinant DNA technology. The medicine is used to treat arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. Patients with ARG1-D have low levels of an enzyme called arginase. This enzyme helps the body control levels of arginine, an amino acid needed by your body to make proteins. If arginine is not controlled it can build up in the body and cause symptoms, like problems with muscle control. Loargys is used in combination with other ways to manage the disease. These may include;

  • a diet that is low in protein
  • food supplements with essential amino acids
  • medicines to manage other symptoms of the disease, such as medicines that lower levels of ammonia in your body. How Loargys works Pegzilarginase, the active substance in Loargys, acts similarly to the natural enzyme arginase, which is lacking or not working properly in patients with ARG1-D. This lowers arginine levels in the blood, thereby reducing the disease symptoms. 2.

What you need to know before you take it

Loargys

You must not be given Loargys if you have had a severe allergic reaction to pegzilarginase or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Loargys may cause allergic reactions. This is most likely to occur after the first few doses, but may also occur later in treatment. 1

If possible, stop the administration immediately and follow your doctor ́s advice, including seeking immediate medical support if you experience any of the following symptoms of a severe allergic reaction: hives, generalised itching, tightness of the chest, difficulty breathing or low blood pressure. Your doctor may decide you need additional medical treatment to either prevent or treat an allergic reaction. During your treatment, your doctor will do blood tests to check what dose of Loargys is right for you. Children and adolescents The medicine should not be used in children under 2 years of age, because it is not known if Loargys is safe and effective in this age group. Other medicines and Loargys Tell your doctor if you are taking, have recently taken or might take any other medicines. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Loargys is not recommended for use if you are pregnant. It is not known if the medicine passes into breast milk. If you are breast-feeding, ask your doctor for advice before taking this medicine. Your doctor will help you decide whether to stop breast-feeding or to stop treatment. Driving and using machines Loargys has no or negligible influence on the ability to drive and use machines. Loargys contains sodium and potassium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodiumfree'. This medicine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially 'potassium-free'. 3.

How to take it

Loargys will be given to you by a healthcare professional. Your doctor will decide the amount of Loargys given to you. The recommended starting dose of Loargys is 0.1 mg per kilogram of your body weight taken once per week. The dose may be increased or decreased by your doctor to keep your blood arginine levels under control. Your doctor will do regular blood tests to check your blood arginine levels and change your dose if needed. Loargys is given as an infusion (drip) directly into your vein or as an injection under the skin, as considered appropriate by your doctor. Your doctor may decide you can be given Loargys at home, as an injection under the skin. After being trained by the doctor or nurse, you can inject Loargys yourself, see instructions in section 7 below. Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist, or nurse if you are not sure. If you are given more Loargys than you should Your doctor will ensure that you receive the right amount of Loargys. If you have been given too much Loargys, your blood arginine level may become too low. Symptoms may include nausea, vomiting, diarrhoea and tiredness. If you or your doctor suspects that you have been given more Loargys than you should, you should be closely monitored and given treatment as needed. 2

If you forget to use Loargys If you have missed a dose of Loargys, contact your doctor to schedule the next dose as soon as possible. You should not be given a double dose to make up for a forgotten dose and there should be at least 4 days between doses. If you stop using Loargys Your doctor will decide if you should stop using Loargys. If you stop using Loargys, your blood arginine level is likely to increase again. If you have any further questions on the use of this medicine, ask your doctor or nurse. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Very common (may affect more than 1 in 10 people)

  • Injection site reaction. Symptoms may include pain, swelling, irritation, redness and rash around the site of injection.
  • Allergic reaction (hypersensitivity). Symptoms may include swelling of your face, skin rash, sudden redness of the skin (flushing) and difficulty breathing (dyspnoea). Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.

How to store it

Loargys

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month. Store in a refrigerator (2 °C – 8 °C). Do not freeze. Store in the original carton in order to protect from light. Once removed from the refrigerator, Loargys can be stored for 2 hours at room temperature up to 25 °C. Do not throw away any medicines via wastewater or household waste. These measures will help protect the environment. 6.

Contents of the pack and other information

What Loargys contains

3

–

The active substance is pegzilarginase. Each 0.4 ml vial contains 2 mg pegzilarginase. Each 1 ml vial contains 5 mg pegzilarginase. The other ingredients are sodium chloride, potassium dihydrogen phosphate, dipotassium phosphate, glycerol, hydrochloric acid, sodium hydroxide and water for injections. Loargys contains sodium and potassium, see section 2.

What Loargys looks like and contents of the pack Loargys is a colourless to slightly yellow or slightly pink, clear to slightly opalescent (pearly) liquid, in a clear glass vial. Each pack contains 1 vial with either 0.4 ml or 1 ml solution for injection/infusion. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Immedica Pharma AB 113 63 Stockholm Sweden This leaflet was last revised in 11/2025. This medicine has been authorised under 'exceptional circumstances'. This means that because of the rarity of this disease it has been impossible to get complete information on this medicine. The Medicines and Healthcare products Regulatory Agency will review any new information on this medicine every year and this leaflet will be updated as necessary. 7.

Instructions for use

The steps below describe how to prepare and give Loargys at home, as an injection under the skin. If you are injecting this medicine yourself, you will be trained how to prepare and inject Loargys by your doctor or nurse. Do not inject this medicine yourself unless you have received training and you understand the steps. Your doctor will prescribe your correct dose and will tell you what volume (in ml) to inject. You may need more than one vial to get the correct dose and you may need to divide the total dose into more than one injection. Your doctor or nurse will tell you exactly what is right for you. Each vial is for single use only, always use new vial(s) for each dose. Loargys should not be mixed with other solutions for injection or infusion. Do not shake. Preparation: Make sure you have everything you need for the injection(s): –

Loargys vial(s) A graduated syringe 1 large needle (e.g. 18 Gauge) per vial, to withdraw the dose 1 small needle (e.g. 26-27 Gauge) per injection Alcohol wipes Gauze pad Plaster, if required Sharps container

4

1. Check the name and the strength of the vial(s) to make sure it contains the correct medicine and that you have the correct number of vials at hand. Check the expiry date on the carton. Do not use if the product has expired. 2. Take the unopened Loargys vial(s) out of the refrigerator 15 to 30 minutes before the planned injection to allow the solution to reach room temperature. Do not use external heat. 3. Wash your hands. 4. The solution in the vial should be colourless to slightly yellow or slightly pink, clear to slightly opalescent (pearly). Do not use if the solution is cloudy or contains visible particles. 5. Place the vial on a clean flat surface. Remove the plastic flip-off cap from the vial. 6. Wipe the top of the vial with an alcohol swab and allow to air dry. Do not touch the top of the vial or allow it to touch anything else once wiped. Withdrawing solution from the vial: 1. Attach a large needle to the graduated syringe. Remove the needle cap. 2. Pull the plunger back to draw air into the graduated syringe, equal to the volume to withdraw from the vial (in ml).

3. Keep the vial on a flat surface, slowly insert the needle through the rubber seal into the vial. a) For single or first vial: The tip of the needle should not touch the solution to avoid forming foam. Continue to step 4.

b) For subsequent vial(s): Turn the vial upside down, ensure the needle tip is in the air space above the solution to avoid forming foam.

4. Slowly push the plunger to inject the air into the vial. 5. Keep the needle in the vial and hold it upside down. With the needle in the solution, slowly pull the plunger to the mark equal to the volume needed.

6. Before removing the needle from the vial, check the solution in the syringe for air bubbles. If there are bubbles, continue to hold the vial upside down with the needle pointing upwards. Gently tap the barrel of the syringe with your finger. Once all the air bubbles are at the top, gently push the plunger to push out the bubbles through the needle. 7. Check the volume to give (in ml), against the markings on the syringe to make sure that you have withdrawn the correct amount of solution. 8. Pull the needle from the vial, put the needle cap back on and dispose it in your sharps container. 9. You may need to use several vials to withdraw the complete volume (in ml). To do this, repeat steps 1-8 above for each vial needed to obtain the total dose (in ml) or as shown to you by your

5

doctor or nurse. Always follow the instructions given to you by your doctor or nurse. Please note that for each new vial you also should use a new needle. 10. Place a small needle on the filled syringe, do not remove the needle cap. Ensure the needle sits tight. Note: If the solution is not to be used immediately, protect the syringe from light. After preparation Loargys can be stored at room temperature (up to 25 °C) for up to 2 hours before administration. After this time, the prepared Loargys cannot be used anymore and must be discarded. Giving the dose: 1. Remove the needle cap. Hold the syringe with the needle pointing up and tap the barrel of the syringe with your finger to remove any air bubbles. Control visually that the volume contained in the syringe is correct. The volume per injection should not exceed 1 ml. If it is the case, multiple injections should be injected at different sites. 2. Choose an injection site (abdomen, side of the thigh, or the side or back of the upper arms). Rotate injection sites between doses. Do not inject into scar tissue or areas that are reddened, inflamed, or swollen. If injecting into the abdomen, avoid the area directly surrounding the navel. If more than 1 injection is needed for a single dose of Loargys, the injection sites should be at least 3 cm apart. 3. Clean the injection site using an alcohol swab and allow the skin to dry. 4. Gently pinch the skin of the chosen injection site between your thumb and index finger.

5. Hold the syringe like a pencil or dart. Insert the needle into the raised skin at a 45° to 90° angle.

6. While continuing to pinch the skin, slowly push the plunger until you have injected the desired volume. Reminder: If you need to inject a volume of more than 1 ml of Loargys, switch the injection site and make sure that the new injection site is more than 3 cm away. Slowly press the plunger down until you have injected the volume needed. Repeat until you have injected your total dose (in ml). Always use a new small needle for each injection. 7. Remove the syringe by pulling it straight out. Release the pinched skin and gently press a gauze pad over the injection site for a few seconds. Apply a plaster if needed. 8. Put your used syringe, needles and caps in the sharps container. Used vials, even if not empty, should be discarded according to your local guidelines.

6

Note the date of the injection and all the sites where you have injected. This helps you to use a different injection site for the next injection. ——————————————————————————————————————-The following information is intended for healthcare professionals only: Loargys is intended for intravenous infusion or subcutaneous injection. Use aseptic technique when preparing and administering Loargys. Do not shake. Instruction for preparation

  • Determine the total volume of Loargys to be administered (and the number of vials needed) based on the patient's weight and dose level.
  • Remove the vial(s) from the refrigerator to reach room temperature.
  • Inspect the vial visually for particulate matter and discoloration prior to administration. o Loargys is a colourless to slightly yellow or slightly pink, clear to slightly opalescent liquid, essentially free of visible foreign particles. o Discard any vial(s) not consistent with this appearance.
  • Withdraw the intended dose into the syringe.
  • Chemical and physical stability for the prepared dose has been demonstrated for 2 hours when stored at room temperature up to 25 °C or up to 4 hours if stored refrigerated at 2 °C to 8 °C. If the product is not used within these time frames, it must be discarded. From a microbiological point of view, the product should be used immediately after reconstitution. For intravenous administration
  • Dilute with sodium chloride 9 mg/ml (0.9 %) solution for injection to achieve the desired volume of infusion (maximum pegzilarginase concentration 0.5 mg/ml).
  • Administer the intravenous infusion over at least 30 minutes.
  • Do not mix other medicines with Loargys or infuse other medicines concomitantly via the same intravenous access line. For subcutaneous administration
  • Administer the undiluted solution as subcutaneous injection into the abdomen, lateral part of the thigh, or the side or back of the upper arms. Rotate injection sites between doses.
  • Do not inject into scar tissue or areas that are reddened, inflamed, or swollen.
  • If injecting into the abdomen, avoid the area directly surrounding the navel.
  • If more than 1 injection is needed for a single dose of Loargys, the injection sites should be at least 3 cm apart. Discard unused portion of the medicine. No special requirements for disposal.

7

Frequently asked questions about Loargys 5 mg/ml solution for injection/infusion

How do I take Loargys 5 mg/ml solution for injection/infusion?

Loargys 5 mg/ml solution for injection/infusion comes as injection containing 5mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Loargys 5 mg/ml solution for injection/infusion?

The active substance in Loargys 5 mg/ml solution for injection/infusion is pegzilarginase.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Loargys 5 mg/ml solution for injection/infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Loargys 5 mg/ml solution for injection/infusion without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Pegzilarginase (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Loargys is indicated for the treatment of arginase 1 deficiency (ARG1‑D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older.

4.2. Posology and method of administration

Treatment should be initiated and supervised by a physician experienced in the management of patients with inherited metabolic diseases.

Posology

Loargys is intended for chronic management of patients with ARG1‑D in conjunction with individualised disease management such as dietary protein restriction, amino acid supplements and pharmacological treatment including nitrogen scavengers.

Loargys should be administered by intravenous infusion or subcutaneous injection, using the same dose. In clinical trials, treatment was initiated as intravenous administration with subsequent transition to subcutaneous administration after 8 weeks, at the earliest (see section 5.1).

The recommended starting dose of Loargys is 0.1 mg/kg once weekly. The dose may be increased or decreased in 0.05 mg/kg increments to achieve therapeutic goals. Doses above 0.2 mg/kg per week have not been studied in clinical trials in ARG1‑D.

Prior to initiating treatment, a baseline plasma arginine concentration should be obtained. After initiating treatment, the weekly dose should be adjusted based on pre-dose plasma arginine concentrations to maintain plasma arginine within the normal range. To maximise the time within the normal range, dose adjustments should be aimed at achieving a pre-dose level of plasma arginine near the upper limit of normal (ULN) (see section 5.1). The dose adjustment should typically be based on two consecutive measurements, and first such assessment performed after 4 weeks of administration. It is recommended to monitor plasma arginine levels weekly for 2 weeks after any dose adjustment to assess impact of the dose change.

Once the individualised dose level has been established, monitoring of plasma arginine concentration is recommended to be performed in accordance with standard clinical monitoring visits, with no longer intervals than 3‑6 months.

Validated methods to monitor arginine levels are to be used in patients treated with Loargys, as standard methods are not adequate to control residual enzyme activity of pegzilarginase after sampling, and may lead to artificially low arginine levels, and incorrect dose adjustments (see section 4.4).

Missed dose

If a dose is missed, administer Loargys as soon as possible. Patients should not be administered 2 doses to make up for the missed dose and should have a minimum of 4 days between doses.

Special population

Elderly population

The safety and efficacy of Loargys in patients older than 65 years have not been established. No data are available.

Hepatic impairment

Hepatic impairment is not expected to impact the recommended Loargys dosing regimen (see section 5.2).

Renal impairment

The safety and efficacy of Loargys in patients with renal impairment have not been established. No data are available. Renal impairment is not expected to impact the recommended Loargys dosing regimen (see section 5.2).

Paediatric population

The posology in the paediatric population aged 2 years and older is the same as in adults.

The safety and efficacy of Loargys in children below 2 years of age have not yet been established. No data are available.

Method of administration

Loargys is intended for intravenous infusion or subcutaneous injection and should be administered by a healthcare professional.

If appropriate, subcutaneous home administration by the patient or caregiver may be considered after at least 8 weeks of treatment, once a stable maintenance dose has been established and the risk for hypersensitivity reactions is assessed as low (see section 4.4). Before self-administration, the patient or caregiver should be adequately trained.

Loargys vial is for single use only.

Determine the total dose and volume of Loargys to be administered (and the number of vials needed) based on the patient's weight (kg) and dose level (mg/kg).

• Calculate the Total dose based on the desired dose level in mg/kg and the patient's weight rounded to a whole number.

Total dose (mg) = Patient weight (kg) × Dose level (mg/kg)

• Calculate the Volume of solution to be administered based on the calculated Total dose and Solution strength. Round the calculated volume to nearest 0.1 ml.

• Calculate the number of vials needed based on the calculated Volume of Loargys. One vial of Loargys contains 0.4 ml or 1 ml solution.

For intravenous administration

• For intravenous infusion, Loargys must be diluted and infused over at least 30 minutes.

• For instructions on preparation and dilution of the medicinal product before administration, see section 6.6.

For subcutaneous administration

• For instructions on preparation and administration of the medicinal product, see section 6.6.

4.3. Contraindications

Severe hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity reactions

Hypersensitivity reactions (such as facial swelling, rash, flushing, dyspnoea) have occurred in Loargys treated subjects with intravenous and subcutaneous administration. The reactions generally occurred with the first few doses, but may also occur later in treatment, see section 4.8 for additional details.

The initial administrations of Loargys should be performed under medical observation.

If a hypersensitivity reaction occurs, appropriate medical treatment should be provided and the patient monitored until signs and symptoms are resolved. The management of hypersensitivity reactions may include temporarily interrupting the administration or lowering the infusion rate and/or treatment with antihistamines and/or corticosteroids. In severe cases stopping the administration and adrenaline treatment may be necessary. Pre‑medication with an antihistamine and/or corticosteroid should be considered in patients who previously have developed a hypersensitivity reaction in connection with pegzilarginase treatment.

In case of home administration by a non-healthcare professional, the patient should be informed of the early signs of severe hypersensitivity reactions e.g., hives, generalised urticaria, tightness of the chest, wheezing and hypotension. Prescription of medication for treatment of a potential severe hypersensitivity reaction should be considered. Patients should also be advised what to do if symptoms of severe hypersensitivity occur which includes seeking immediate medical support.

Monitoring of plasma arginine

Pegzilarginase will interfere with routine arginine laboratory analysis, resulting in erroneous low measurements due to post-collection degradation of arginine. The testing laboratory should be informed that the patient is treated with a medicinal product that metabolises and reduces arginine levels. Alternative validated sampling procedures to measure arginine must be used in patients treated with Loargys. This includes CE-marked blood collection tubes containing the enzyme-blocker nor‑NOHA.

Populations not studied in clinical trials

No data from clinical trials are available in middle-age and elderly patients with long-existing motoric impairment, or in patients with arginine levels near 200 µM on dietary protein restriction alone. Extrapolation of the treatment effects as shown in the clinical trial population is unclear (see section 5.1). The benefit-risk need to be determined on an individual basis in these patients.

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

This medicinal product contains less than 1 mmol potassium (39 mg) per dose, that is to say essentially 'potassium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. Pegzilarginase is a recombinant human enzyme and therefore no cytochrome P450 mediated drug-drug interactions are expected.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no or limited data from the use of pegzilarginase in pregnant women.

Studies in animals have shown reproductive toxicity (see section 5.3).

Pegzilarginase is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

It is unknown whether pegzilarginase is excreted in human or animal milk.

A risk to the breastfed new-born/infant cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Loargys therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Fertility

No human data are available. In animal studies, pegzilarginase produced effects on spermatogenesis and reduced female fertility (see section 5.3).

4.7. Effects on ability to drive and use machines

Loargys has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

Summary of the safety profile

The most commonly reported adverse reactions in patients in clinical trials were injection site reactions (13.6%) and hypersensitivity (12.5%).

Tabulated list of adverse reactions

Assessment of adverse reactions was based on exposure in 48 ARG1‑D patients (8 adults and 40 children between the ages of 2 and 31 years at enrolment) with treatment duration of up to approximately 5 years across 3 clinical trials.

Adverse reactions are listed by MedDRA system organ class and by frequency in Table 1 below. Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000); not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Due to the small size of the medicinal product safety ARG1‑D population database (N=48), the adverse reaction frequency for uncommon, rare and very rare could not be reliably estimated.

Table 1: Adverse reactions

System organ class

Very common

Immune system disorders

Hypersensitivity

General disorders and administration site conditions

Injection site reactions

Description of selected adverse reactions

Hypersensitivity

Hypersensitivity reactions with symptoms including facial swelling, rash, flushing and dyspnoea have been reported. In clinical trials, when administered intravenously, 6 of 48 (12.5%) Loargys-treated patients, experienced signs and symptoms either consistent with, or that may be related to a hypersensitivity reaction. The reactions generally occurred with the first few doses. The reactions were mild or moderate and resolved spontaneously, or rapidly after treatment with standard medical care. None of the reactions led to discontinuation of treatment. In the clinical trials, pre-medication with non-sedating antihistamines was considered on an individual basis prior to administration (see section 4.4).

Post-marketing, hypersensitivity reactions were reported, even involving patients treated by subcutaneous administration who were pre-medicated with antihistamines.

Injection site reactions

Injection site reactions were reported in 13.6% (6/44) of Loargys-treated patients after subcutaneous administration. Signs and symptoms included pain, erythema, swelling, irritation and rash at the injection site. The injection site reactions were mild in severity and resolved spontaneously or with standard medical care without dose interruption.

Immunogenicity

There is potential for immunogenicity to pegylated therapeutic proteins. The observed incidence of anti-drug antibodies (ADAs) is highly dependent on the sensitivity and specificity of the assay. Across all clinical trials in the pegzilarginase ARG1‑D development program, 12 of 48 subjects (25%) tested positive for ADAs against PEG and/or the protein moiety of pegzilarginase, with the majority detected early after the first dose. There was no assay available for detecting neutralising antibodies during the clinical development programme. The ADAs were transient in nature and resolved during continued treatment. The presence of ADAs was associated with transient changes in the pharmacokinetics (PK) and pharmacodynamics (PD) of Loargys in patients with ARG1‑D.

Paediatric population

The majority of patients treated with pegzilarginase in the ARG1‑D development programme were paediatric patients with 88% (40/48) being children (2-18 years old). The safety profile of pegzilarginase presented in the safety section is therefore considered representative for the paediatric population above 2 years.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Potential effects from an overdose would likely be an exaggerated pharmacologic effect of pegzilarginase resulting in abnormally low plasma arginine levels (see section 5.3).

In an oncology Phase 1 trial in subjects with advanced solid tumours, 1 subject inadvertently received 1.6 mg/kg of pegzilarginase (16 × the recommended initial dose of 0.1 mg/kg in ARG1‑D patients). The subject developed nausea, vomiting, diarrhoea, and fatigue, and was successfully treated with intravenous supportive care without sequelae.

Patients suspected of receiving an overdose should be closely monitored and general supportive measures should be initiated.

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • LoargysPegzilarginasum · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Loargys 5 mg/ml solution for injection/infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →